Valuation
- Market cap
- 976,177,000
- Revenue TTM
- $0
- Net income TTM
- $-227,320,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.23
Trading
- Volume
- 1,827,800
- Avg volume
- 1,457,856
- Day's range
- $11.03 – $11.65
- Shares out
- 85,107,000
- Stochastic %K
- 14%
- Beta
- 1.09
- Analysts
- Strong Sell
- Price target
- $33.46
Company profile
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and p...
Show more
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 41 415108022
- Website
- https://www.moonlaketx.com
- Address
- Dorfstrasse 29, Zug, Switzerland
Latest news
No headlines yet.
